These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 24119546)

  • 1. Choosing Alzheimer's disease prevention clinical trial populations.
    Grill JD; Monsell SE
    Neurobiol Aging; 2014 Mar; 35(3):466-71. PubMed ID: 24119546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of Cognitive Decline for Enrichment of Alzheimer's Disease Clinical Trials.
    Tam A; Laurent C; Gauthier S; Dansereau C
    J Prev Alzheimers Dis; 2022; 9(3):400-409. PubMed ID: 35841241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative.
    Grill JD; Di L; Lu PH; Lee C; Ringman J; Apostolova LG; Chow N; Kohannim O; Cummings JL; Thompson PM; Elashoff D;
    Neurobiol Aging; 2013 Jan; 34(1):62-72. PubMed ID: 22503160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and sample size considerations for Alzheimer's disease prevention trials using multistate models.
    Brookmeyer R; Abdalla N
    Clin Trials; 2019 Apr; 16(2):111-119. PubMed ID: 30922116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Independent effects of white matter hyperintensities on cognitive, neuropsychiatric, and functional decline: a longitudinal investigation using the National Alzheimer's Coordinating Center Uniform Data Set.
    Puzo C; Labriola C; Sugarman MA; Tripodis Y; Martin B; Palmisano JN; Steinberg EG; Stein TD; Kowall NW; McKee AC; Mez J; Killiany RJ; Stern RA; Alosco ML
    Alzheimers Res Ther; 2019 Jul; 11(1):64. PubMed ID: 31351489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of APOE genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer's disease.
    Kennedy RE; Cutter GR; Schneider LS
    Alzheimers Dement; 2014 May; 10(3):349-59. PubMed ID: 23712001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE).
    Jessen F; Spottke A; Boecker H; Brosseron F; Buerger K; Catak C; Fliessbach K; Franke C; Fuentes M; Heneka MT; Janowitz D; Kilimann I; Laske C; Menne F; Nestor P; Peters O; Priller J; Pross V; Ramirez A; Schneider A; Speck O; Spruth EJ; Teipel S; Vukovich R; Westerteicher C; Wiltfang J; Wolfsgruber S; Wagner M; Düzel E
    Alzheimers Res Ther; 2018 Feb; 10(1):15. PubMed ID: 29415768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attitudes toward clinical trials across the Alzheimer's disease spectrum.
    Nuño MM; Gillen DL; Dosanjh KK; Brook J; Elashoff D; Ringman JM; Grill JD
    Alzheimers Res Ther; 2017 Oct; 9(1):81. PubMed ID: 28978335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GeneMatch: A novel recruitment registry using at-home APOE genotyping to enhance referrals to Alzheimer's prevention studies.
    Langbaum JB; Karlawish J; Roberts JS; Wood EM; Bradbury A; High N; Walsh TL; Gordon D; Aggarwal R; Davis P; Stowell C; Trisko L; Langlois CM; Reiman EM; Tariot PN
    Alzheimers Dement; 2019 Apr; 15(4):515-524. PubMed ID: 30772251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. APOE-related risk of mild cognitive impairment and dementia for prevention trials: An analysis of four cohorts.
    Qian J; Wolters FJ; Beiser A; Haan M; Ikram MA; Karlawish J; Langbaum JB; Neuhaus JM; Reiman EM; Roberts JS; Seshadri S; Tariot PN; Woods BM; Betensky RA; Blacker D
    PLoS Med; 2017 Mar; 14(3):e1002254. PubMed ID: 28323826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Trial-Ready Cohort for Preclinical and Prodromal Alzheimer's Disease (TRC-PAD): Experience from the First 3 Years.
    Walter S; Langford OG; Clanton TB; Jimenez-Maggiora GA; Raman R; Rafii MS; Shaffer EJ; Sperling RA; Cummings JL; Aisen PS
    J Prev Alzheimers Dis; 2020; 7(4):234-241. PubMed ID: 32920625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selegiline for Alzheimer's disease.
    Birks J; Flicker L
    Cochrane Database Syst Rev; 2003; (1):CD000442. PubMed ID: 12535396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors influencing attrition in 35 Alzheimer's Disease Centers across the USA: a longitudinal examination of the National Alzheimer's Coordinating Center's Uniform Data Set.
    Burke SL; Hu T; Naseh M; Fava NM; O'Driscoll J; Alvarez D; Cottler LB; Duara R
    Aging Clin Exp Res; 2019 Sep; 31(9):1283-1297. PubMed ID: 30535620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for Reduced Autobiographical Memory Episodic Specificity in Cognitively Normal Middle-Aged and Older Individuals at Increased Risk for Alzheimer's Disease Dementia.
    Grilli MD; Wank AA; Bercel JJ; Ryan L
    J Int Neuropsychol Soc; 2018 Nov; 24(10):1073-1083. PubMed ID: 30136918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of High-Frequency In-Home Monitoring Data May Reduce Sample Sizes Needed in Clinical Trials.
    Dodge HH; Zhu J; Mattek NC; Austin D; Kornfeld J; Kaye JA
    PLoS One; 2015; 10(9):e0138095. PubMed ID: 26379170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apolipoprotein E genotype influences cognitive 'phenotype' in patients with Alzheimer's disease but not in healthy control subjects.
    Smith GE; Bohac DL; Waring SC; Kokmen E; Tangalos EG; Ivnik RJ; Petersen RC
    Neurology; 1998 Feb; 50(2):355-62. PubMed ID: 9484353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals.
    Petersen RC; Smith GE; Ivnik RJ; Tangalos EG; Schaid DJ; Thibodeau SN; Kokmen E; Waring SC; Kurland LT
    JAMA; 1995 Apr; 273(16):1274-8. PubMed ID: 7646655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease.
    Lim YY; Maruff P; Pietrzak RH; Ames D; Ellis KA; Harrington K; Lautenschlager NT; Szoeke C; Martins RN; Masters CL; Villemagne VL; Rowe CC;
    Brain; 2014 Jan; 137(Pt 1):221-31. PubMed ID: 24176981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurofibrillary Tangle Stage and the Rate of Progression of Alzheimer Symptoms: Modeling Using an Autopsy Cohort and Application to Clinical Trial Design.
    Qian J; Hyman BT; Betensky RA
    JAMA Neurol; 2017 May; 74(5):540-548. PubMed ID: 28288263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimizing the Sample Sizes of Clinical Trials on Preclinical and Early Symptomatic Stage of Alzheimer Disease.
    Luo J; Weng H; Morris JC; Xiong C
    J Prev Alzheimers Dis; 2018; 5(2):110-119. PubMed ID: 29616704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.